Science, Technology, Engineering and Mathematics.
Open Access

EXPRESSION AND PROGNOSTIC ROLE OF TGF-Β AND EMP-1 IN INTERMEDIATE AND ADVANCED ESOPHAGEAL SQUAMOUS CELL CARCINOMA

Download as PDF

Volume 6, Issue 3, Pp 39-44, 2024

DOI: 10.61784/jpmr3014

Author(s)

Qi Wang*, ChangHai Tuo, Fei Fu, Lin Tian*

Affiliation(s)

Department of Pathology, Renmin Hospital, Hubei University of Medicine, Shiyan 442000, Hubei, China.

Corresponding Author

Qi Wang, Lin Tian

ABSTRACT

Objective: To investigate the expression of transforming growth factor- β (TGF-β) and epithelial membrane protein 1 (EMP-1) in middle and advanced esophageal squamous cell carcinoma (ESCC) and its role on tumor progression, and to define the role of TGF-β and EMP-1 as pro-cancer and tumor suppressors. Methods: The expression levels of TGF-β and EMP-1 in carcinoma and adjacent tissues of 60 ESCC patients. The correlation of both expression was explored by Spearman correlation analysis and their impact on patient outcomes was assessed by Kaplan-Meier survival analysis. Results: TGF-βexpression was significantly higher in ESCC carcinoma tissues than adjacent tissues (P <0.05), while EMP-1 expression was significantly lower in adjacent tissues (P <0.05). The prognosis of patients with high TGF-β expression and low EMP-1 expression was significantly worse than that in the other groups (P <0.05). Conclusions: TGF-β plays a role as a cancer-promoting factor in ESCC, while EMP-1 is downregulated as a tumor suppressor, suggesting the importance of both in cancer progression. Their expression levels can be used as potential markers to predict the prognosis of ESCC patients.

KEYWORDS

Tumor microenvironment; ESCC; Biomarkers; TGF-β; EMP1

CITE THIS PAPER

Qi Wang, ChangHai Tuo, Fei Fu, Lin Tian. Expression and prognostic role of TGF-Β and EMP-1 in intermediate and advanced esophageal squamous cell carcinoma. Journal of Pharmaceutical and Medical Research. 2024, 6(3): 39-44. DOI: 10.61784/jpmr3014.

REFERENCES

[1] Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: a cancer journal for clinicians, 2021, 71(3): 209-249.

[2] Ustgi AK, El-Serag HB. Esophageal carcinoma. The New England journal of medicine, 2014, 371(26): 2499-509.

[3] Pennathur A, Gibson MK, Jobe BA, et al. Oesophageal carcinoma. Lancet (London, England), 2013, 381(9864): 400-412.

[4] Lagergren J, Smyth E, Cunningham D, et al. Oesophageal cancer. Lancet (London, England), 2017, 390(10110): 2383-2396.

[5] Massagué J. TGFbeta in Cancer. Cell, 2008, 134(2): 215-230.

[6] Seoane J. The TGFBeta pathway as a therapeutic target in cancer. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2008, 10(1): 14-19.

[7] Xu J, Lamouille S, Derynck R. TGF-beta-induced epithelial to mesenchymal transition. Cell research, 2009, 19(2): 156-172.

[8] Ikushima H, Miyazono K. TGFbeta signalling: a complex web in cancer progression. Nature reviews Cancer, 2010, 10(6): 415-424.

[9] Ahmat Amin MKB, Shimizu A, Zankov DP, et al. Epithelial membrane protein 1 promotes tumor metastasis by enhancing cell migration via copine-III and Rac1. Oncogene, 2018, 37(40): 5416-5434.

[10] Wang M, Liu T, Hu X, et al. EMP1 promotes the malignant progression of osteosarcoma through the IRX2/MMP9 axis. Panminerva medica, 2020, 62(3): 150-154.

[11] Wilson HL, Wilson SA, Surprenant A, et al. Epithelial membrane proteins induce membrane blebbing and interact with the P2X7 receptor C terminus. The Journal of biological chemistry, 2002, 277(37): 34017-34023.

[12] Padua D, Massagué J. Roles of TGFbeta in metastasis. Cell research, 2009, 19(1): 89-102.

[13] Kang Y, Massagué J. Epithelial-mesenchymal transitions: twist in development and metastasis. Cell, 2004, 118(3): 277-279.

[14] Shi Y, Massagué J. Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell, 2003, 113(6): 685-700.

[15] Liu S, Shi J, Wang L, et al. Loss of EMP1 promotes the metastasis of human bladder cancer cells by promoting migration and conferring resistance to ferroptosis through activation of PPAR gamma signaling. Free radical biology & medicine, 2022, 189: 42-57.

[16] Sato A, Rahman NIA, Shimizu A, et al. Cell-to-cell contact-mediated regulation of tumor behavior in the tumor microenvironment. Cancer science, 2021, 112(10): 4005-4012.

[17] Wang J, Li X, Wu H, et al. EMP1 regulates cell proliferation, migration, and stemness in gliomas through PI3K-AKT signaling and CD44. Journal of cellular biochemistry, 2019, 120(10): 17142-17150.

[18] Batlle E, Massagué J. Transforming Growth Factor-β Signaling in Immunity and Cancer. Immunity, 2019, 50(4): 924-940.

[19] Derynck R, Zhang YE. Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature, 2003, 425(6958): 577-584.

[20] Yang L, Pang Y, Moses HL. TGF-beta and immune cells: an important regulatory axis in the tumor microenvironment and progression. Trends in immunology, 2010, 31(6): 220-227.

All published work is licensed under a Creative Commons Attribution 4.0 International License. sitemap
Copyright © 2017 - 2024 Science, Technology, Engineering and Mathematics.   All Rights Reserved.